309 related articles for article (PubMed ID: 18956370)
1. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
[TBL] [Abstract][Full Text] [Related]
2. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
3. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
4. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
5. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
6. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
8. A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.
Qu P; Ma JH; Zhang XM; Huang XJ; Yang XW; Yan-Fang S
Indian J Exp Biol; 2010 May; 48(5):436-43. PubMed ID: 20795360
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
Woo WP; Doan T; Herd KA; Netter HJ; Tindle RW
J Virol; 2006 Apr; 80(8):3975-84. PubMed ID: 16571814
[TBL] [Abstract][Full Text] [Related]
10. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
11. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Lonchay C; van der Bruggen P; Connerotte T; Hanagiri T; Coulie P; Colau D; Lucas S; Van Pel A; Thielemans K; van Baren N; Boon T
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14631-8. PubMed ID: 15452345
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
Hu X; Chakraborty NG; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
Cancer Res; 1996 Jun; 56(11):2479-83. PubMed ID: 8653680
[TBL] [Abstract][Full Text] [Related]
13. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
[TBL] [Abstract][Full Text] [Related]
14. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
16. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.
Pascolo S; Schirle M; Gückel B; Dumrese T; Stumm S; Kayser S; Moris A; Wallwiener D; Rammensee HG; Stevanovic S
Cancer Res; 2001 May; 61(10):4072-7. PubMed ID: 11358828
[TBL] [Abstract][Full Text] [Related]
17. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
19. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
20. [Establishment of B16-HLA-MAGE-3 melanoma cell line coexpressing HLA-A 0201/K(b) and MAGE-3 and its role in tumor vaccine evaluation].
Song SX; Yan CZ; Zheng L; You HY; Wang JX; Liu FY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jul; 24(7):679-82. PubMed ID: 18616910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
